All In Biotech

Drug Trial Radar · NCT04559971

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

A Randomised, Double-blind, Placebo-controlled Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SLN124 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 3, 2020

Primary completion

Mar 23, 2021

Study completion Mar 23, 2021

Sponsor

Lead sponsor
Silence Therapeutics plcIndustry
Sponsor type
Industry
First posted
Sep 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and tolerability of SLN124 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • SLN124Drug

    SLN124 for subcutaneous (s.c.) injection

  • PlaceboDrug

    Sodium chloride for s.c. injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hammersmith Medicines Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.